Top Markets
#1 Islamic Coin Islamic Coin +151.49%
#2 DOVU DOVU +48.08%
#3 Akedo Akedo +40.50%
#4 Velvet Velvet +35.26%
#5 Black Phoenix Black Phoenix +34.23%
#6 Cross Cross +19.18%
#7 DoubleZero DoubleZero +18.36%
#8 Tutorial Tutorial +15.48%
#9 Cap Cap +14.84%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +10.23%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Oxurion N.V. Oxurion N.V.

Oxurion N.V.

OXUR
株式のランク #39565
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
株価
$0.003084
時価総額
$434.03K
変化（1日）
-7.14%
変化（1年）
-89.24%
国
BE
取引 Oxurion N.V. (OXUR)

カテゴリー

Healthcare
Oxurion N.V.（OXUR）の収益
Aug 2026 時点の収益 TTM: 0
Oxurion N.V. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Oxurion N.V. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE